Melanoma Research Victoria

Source: Targeted Oncology, March 2019 Current treatment paradigms for melanoma indicate that most patients with node-positive, stage III disease will go on to receive adjuvant therapy with either anti–PD-1 immunotherapy or targeted BRAF/MEK inhibitor combinations, according to a presentation by Sanjiv S. Agarwala, MD, of St. Luke’s Cancer Center in Bethlehem, Pennsylvania.1 In his presentation at […]

Read the full story

Source: The University Of Queensland, February 2019 As Queenslanders flock to the outdoors this Australia Day weekend, University of Queensland researchers are investigating whether text messages could prevent people falling victim to sunburn. UQ is recruiting 500 Queenslanders to join the Sun Text Project, a text messaging study about staying safe in the sun. Professor Monika […]

Read the full story

Source: Medical Express, February 2019 Injection of a genetically modified virus that induces the body’s own immune cells to attack metastatic melanoma effectively treated almost 40 percent of patients with tumors that could not be surgically removed, according to researchers from three prominent cancer centers in a study published as an “article in press” on the Journal of […]

Read the full story

Source: Combination therapy with vemurafenib plus cobimetinib after immunotherapy may cause cutaneous adverse events (CAEs) in patients with BRAF-mutant metastatic melanoma. These findings are based on the results of a retrospective chart review of patients with BRAF-mutant metastatic melanoma receiving sequential treatment with immunotherapy followed by targeted therapy or vice versa. This study was published in the Journal […]

Read the full story